Hector Novoa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hector Novoa has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Holden
Department of Interventional Radiology, Auckland Hospital, Auckland, New Zealand
2 shared publications - Austin Phillips
W L Gore & Associates, Inc, Flagstaff, AZ, United States
2 shared publications - Darren B. Schneider
Division of Vascular Surgery and Endovascular Therapy University of Pennsylvania Philadelphia, PA United States
2 shared publications - Ehrin J. Armstrong
Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of Colorado, Denver, CO, USA
2 shared publications - Markus Steinbauer
Klinik für Gefäßchirurgie, Krankenhaus Barmherzige Brüder, Regensburg, Deutschland
2 shared publications - Melissa L. Kirkwood
Division of Vascular and Endovascular Surgery, Department of Surgery, University Of Texas Southwestern Medical Center, Dallas, TX
2 shared publications
Latest Publications
- Open Access
- 4 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e51480
FORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial
Background: The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. Objective: The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. Methods: A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. Results: Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. Conclusions: The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. Trial Registration: ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 International Registered Report Identifier (IRRID): PRR1-10.2196/51480
- 4 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e51480
Open AccessFORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial
Background: The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. Objective: The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. Methods: A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. Results: Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. Conclusions: The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. Trial Registration: ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 International Registered Report Identifier (IRRID): PRR1-10.2196/51480
- Open Access
- 30 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Patent Foramen Ovale Closure with the GORE® CARDIOFORM Septal Occluder for Migraine Headache Relief: The Prospective, Randomized, Placebo-, Sham-Controlled RELIEF Study (Preprint)
BACKGROUND The patent foramen ovale (PFO), a remnant of normal fetal circulation, has been associated with migraine. Sham-controlled clinical trials have yet to conclusively demonstrate that PFO closure reduces migraine attack frequency. Recent observational studies have suggested that a reduction in migraine headache frequency after treatment with P2Y12 platelet receptor inhibitors (thienopyridines) may be used to identify those in whom PFO plays a pathogenic role. OBJECTIVE This article details the background, rationale, design, and planned procedures for the multicenter, prospective, randomized, placebo- and sham-controlled GORE® CARDIOFORM Septal Occluder Migraine Clinical Study (RELIEF). METHODS The study will evaluate closure of the PFO for migraine headache relief in an enriched population comprised of patients pre-treated successfully with thienopyridines. Approximately 25 sites in the United States will randomize 150 patients (1:1), blinded, to receive either PFO closure or a sham procedure. The primary efficacy endpoint is comparison of reduction from baseline in the mean monthly migraine headache days between the PFO closure (N=75) and the sham procedure cohorts (N=75). RESULTS Outcomes will be reported following study completion. CONCLUSIONS The inclusion criterion of successful pre-treatment with thienopyridine may allow for selection of patients with migraine in whom the PFO is playing a causal role in symptom expression and identify a PFO closure-responsive subgroup. CLINICALTRIAL The study is registered with ClinicalTrials.gov (NCT04100135).
- 30 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPatent Foramen Ovale Closure with the GORE® CARDIOFORM Septal Occluder for Migraine Headache Relief: The Prospective, Randomized, Placebo-, Sham-Controlled RELIEF Study (Preprint)
BACKGROUND The patent foramen ovale (PFO), a remnant of normal fetal circulation, has been associated with migraine. Sham-controlled clinical trials have yet to conclusively demonstrate that PFO closure reduces migraine attack frequency. Recent observational studies have suggested that a reduction in migraine headache frequency after treatment with P2Y12 platelet receptor inhibitors (thienopyridines) may be used to identify those in whom PFO plays a pathogenic role. OBJECTIVE This article details the background, rationale, design, and planned procedures for the multicenter, prospective, randomized, placebo- and sham-controlled GORE® CARDIOFORM Septal Occluder Migraine Clinical Study (RELIEF). METHODS The study will evaluate closure of the PFO for migraine headache relief in an enriched population comprised of patients pre-treated successfully with thienopyridines. Approximately 25 sites in the United States will randomize 150 patients (1:1), blinded, to receive either PFO closure or a sham procedure. The primary efficacy endpoint is comparison of reduction from baseline in the mean monthly migraine headache days between the PFO closure (N=75) and the sham procedure cohorts (N=75). RESULTS Outcomes will be reported following study completion. CONCLUSIONS The inclusion criterion of successful pre-treatment with thienopyridine may allow for selection of patients with migraine in whom the PFO is playing a causal role in symptom expression and identify a PFO closure-responsive subgroup. CLINICALTRIAL The study is registered with ClinicalTrials.gov (NCT04100135).
- Open Access
- 1 August 2023
- Published by JMIR Publications Inc. in JMIR Preprints
FORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial (Preprint)
BACKGROUND The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. OBJECTIVE The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. METHODS A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. RESULTS Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. CONCLUSIONS The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. CLINICALTRIAL ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/51480
- 1 August 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial (Preprint)
BACKGROUND The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. OBJECTIVE The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. METHODS A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. RESULTS Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. CONCLUSIONS The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. CLINICALTRIAL ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/51480